Inventiva SA
PAR:IVA
Inventiva SA
Depreciation & Amortization
Inventiva SA
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Inventiva SA
PAR:IVA
|
Depreciation & Amortization
-€3.2m
|
CAGR 3-Years
-51%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Depreciation & Amortization
-€7.4m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
5%
|
|
|
Nanobiotix SA
PAR:NANO
|
Depreciation & Amortization
-€1.9m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-30%
|
|
|
Innate Pharma SA
PAR:IPH
|
Depreciation & Amortization
-€2.6m
|
CAGR 3-Years
19%
|
CAGR 5-Years
26%
|
CAGR 10-Years
-5%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Depreciation & Amortization
-€1.5m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
19%
|
CAGR 10-Years
-20%
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Depreciation & Amortization
-€8.4m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-18%
|
|
Inventiva SA
Glance View
Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. The company is headquartered in Daix, Occitanie and currently employs 100 full-time employees. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
See Also
What is Inventiva SA's Depreciation & Amortization?
Depreciation & Amortization
-3.2m
EUR
Based on the financial report for Jun 30, 2024, Inventiva SA's Depreciation & Amortization amounts to -3.2m EUR.
What is Inventiva SA's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
-23%
Over the last year, the Depreciation & Amortization growth was -13%. The average annual Depreciation & Amortization growth rates for Inventiva SA have been -51% over the past three years , -23% over the past five years .
You don't have any saved screeners yet